Abstract
BackgroundComparisons of clinical trial findings in systematic reviews can be hindered by the heterogeneity of the outcomes reported. Moreover, the outcomes that matter most to patients might be underreported. A core outcome set can address these issues, as it defines a minimum set of outcomes that should be reported in all clinical trials in a particular area of research. The objective in this study was to develop a core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy.MethodsFirstly, eligible outcomes were identified through a systematic review of trials of medication review in older patients (≥65 years) and interviews with 15 older patients. Secondly, an international three-round Delphi survey in four countries involving patients, healthcare professionals, and experts was conducted to validate outcomes to be included in the core outcome set. Consensus meetings were conducted to validate the results.ResultsOf the 164 participants invited to take part in the Delphi survey, 150 completed Round 1, including 55 patients or family caregivers, 55 healthcare professionals, and 40 experts. A total of 129 participants completed all three rounds. Sixty-four eligible outcomes were extracted from 47 articles, 32 clinical trial protocols, and patient interviews. Thirty outcomes were removed and one added after Round 1, 18 outcomes were removed after Round 2, and seven after Round 3. Results were discussed during consensus meetings. Consensus was reached on seven outcomes, which constitute the core outcome set: drug-related hospital admissions; drug overuse; drug underuse; potentially inappropriate medications; clinically significant drug-drug interactions; health-related quality of life; pain relief.ConclusionsWe developed a core outcome set of seven outcomes which should be used in future trials of medication review in multi-morbid older patients with polypharmacy.
Highlights
Comparisons of clinical trial findings in systematic reviews can be hindered by the heterogeneity of the outcomes reported
A core outcome set (COS) defines a minimum set of outcomes to be reported in all clinical trials in a particular research area
The interpretative approach identified 19 outcomes, seven of which had not been identified in the systematic review
Summary
Comparisons of clinical trial findings in systematic reviews can be hindered by the heterogeneity of the outcomes reported. A core outcome set can address these issues, as it defines a minimum set of outcomes that should be reported in all clinical trials in a particular area of research. The objective in this study was to develop a core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy. Patients aged 65 and older are often exposed to polypharmacy in a multi-morbidity context [1, 2] This increases medication costs and the risk of adverse drug reactions [3,4,5,6]. A core outcome set (COS) defines a minimum set of outcomes to be reported in all clinical trials in a particular research area. Outcomes that are highly relevant to older adults are often ignored in RCTs [27, 28]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
